219 related articles for article (PubMed ID: 33634446)
1. Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients.
Milling TJ; King B; Yue P; Middeldorp S; Beyer-Westendorf J; Eikelboom JW; Crowther M; Xu L; Verhamme P; Siegal DM; Connolly SJ;
Thromb Haemost; 2021 Aug; 121(8):1097-1106. PubMed ID: 33634446
[TBL] [Abstract][Full Text] [Related]
2. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
[TBL] [Abstract][Full Text] [Related]
3. Restart TICrH: An Adaptive Randomized Trial of Time Intervals to Restart Direct Oral Anticoagulants after Traumatic Intracranial Hemorrhage.
Milling TJ; Warach S; Johnston SC; Gajewski B; Costantini T; Price M; Wick J; Roward S; Mudaranthakam D; Dula AN; King B; Muddiman A; Lip GYH
J Neurotrauma; 2021 Jun; 38(13):1791-1798. PubMed ID: 33470152
[TBL] [Abstract][Full Text] [Related]
4. Is It Truly "Alpha"? Incidence of Thrombotic Events With Andexanet Alfa at a Single Academic Medical Center.
Parsels KA; Seabury RW; Darko W; Probst LA; Cwikla GM; Miller CD
Ann Emerg Med; 2020 May; 75(5):675-676. PubMed ID: 32336435
[No Abstract] [Full Text] [Related]
5. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
[TBL] [Abstract][Full Text] [Related]
6. Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban.
Benz AP; Xu L; Eikelboom JW; Middeldorp S; Milling TJ; Crowther M; Yue P; Conley P; Lu G; Connolly SJ;
Thromb Haemost; 2022 Jun; 122(6):998-1005. PubMed ID: 34996121
[TBL] [Abstract][Full Text] [Related]
7. What is the role of andexanet alfa in the reversal of anticoagulant effects?
Sewell JH; Williams L; McKnight E; Nguyen A; Sarac M
JAAPA; 2021 Jan; 34(1):8-9. PubMed ID: 33332828
[TBL] [Abstract][Full Text] [Related]
8. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Connolly SJ; Milling TJ; Eikelboom JW; Gibson CM; Curnutte JT; Gold A; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Goodman S; Leeds J; Wiens BL; Siegal DM; Zotova E; Meeks B; Nakamya J; Lim WT; Crowther M;
N Engl J Med; 2016 Sep; 375(12):1131-41. PubMed ID: 27573206
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation.
Yanagisawa D; Abe K; Amano H; Komatsuda S; Honda T; Manabe D; Yamamoto H; Kozuma K; Kodashima S; Asaoka Y; Yamamoto T; Tanaka A
PLoS One; 2021; 16(11):e0260585. PubMed ID: 34843582
[TBL] [Abstract][Full Text] [Related]
10. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
[TBL] [Abstract][Full Text] [Related]
11. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence.
Abdulrehman J; Eikelboom JW; Siegal DM
Future Cardiol; 2019 Nov; 15(6):395-404. PubMed ID: 31668083
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
13. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
Huisman MV; Fanikos J
Am J Emerg Med; 2016 Nov; 34(11S):46-51. PubMed ID: 27697438
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
Nederpelt CJ; Naar L; Sylvester KW; Barra ME; Roberts RJ; Velmahos GC; Kaafarani HMA; Rosenthal MG; King DR
J Thromb Haemost; 2020 Oct; 18(10):2532-2541. PubMed ID: 32738161
[TBL] [Abstract][Full Text] [Related]
15. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
[TBL] [Abstract][Full Text] [Related]
16. Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti-Xa concentrations.
Dinunno CV; Lopez CN; Succar L; Nguyen DT; Graviss EA; Salazar E; Donahue KR
Pharmacotherapy; 2022 Oct; 42(10):768-779. PubMed ID: 36054446
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
Coleman CI; Baker WL; Meinecke AK; Eriksson D; Martinez BK; Bunz TJ; Alberts MJ
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):159-166. PubMed ID: 31549153
[TBL] [Abstract][Full Text] [Related]
18. Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding.
Kimpton M; Siegal DM
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):204-208. PubMed ID: 31808849
[TBL] [Abstract][Full Text] [Related]
19. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study.
Schulman S; Gross PL; Ritchie B; Nahirniak S; Lin Y; Lieberman L; Carrier M; Crowther MA; Ghosh I; Lazo-Langner A; Zondag M;
Thromb Haemost; 2018 May; 118(5):842-851. PubMed ID: 29564837
[TBL] [Abstract][Full Text] [Related]
20. Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.
Reynolds TR; Gilbert BW; Hall KM
J Pharm Pract; 2021 Oct; 34(5):755-760. PubMed ID: 32089040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
